Opko Health, Inc.

🇨🇱Chile

Country: 🇨🇱Chile

Ownership: Public

Established: 2005-01-01

Employees: 3.9K

Market Cap: -

Website: http://www.opko.com

Clinical Trials

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

Phase 1

Completed

Conditions: Prostate Cancer
Bone Neoplasms
Hyperparathyroidism, Secondary
Breast Cancer
Hypocalcemia

Interventions: Drug: CTAP101 Capsules

First Posted Date: 2014-10-24

Last Posted Date: 2019-09-27

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 33

Registration Number: NCT02274623

Locations: 🇺🇸
Coast Hematology-Oncology Associates, Long Beach, California, United States
🇺🇸
Research by Design LLC, Evergreen Park, Illinois, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 3 locations

A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: LY2944876
Drug: Placebo

First Posted Date: 2014-07-11

Last Posted Date: 2021-05-27

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 48

Registration Number: NCT02188303

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Exenatide extended-release
Drug: LY2944876
Drug: Placebo
Drug: Metformin

First Posted Date: 2014-04-22

Last Posted Date: 2021-05-27

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 420

Registration Number: NCT02119819

Locations: 🇺🇸
Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States
🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timisoara, Romania
🇵🇷
Manati Medical Center, Manati, Puerto Rico

and more 31 locations

A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

Phase 3

Terminated

Conditions: Adult Growth Hormone Deficiency

Interventions: Drug: MOD-4023
Other: Placebo

First Posted Date: 2013-07-26

Last Posted Date: 2022-08-12

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 202

Registration Number: NCT01909479

Locations: 🇮🇱
Opko Biologics, Kiryat Gat, Israel

A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

Phase 2

Completed

Conditions: Down Syndrome

Interventions: Drug: ELND005
Drug: Placebo

First Posted Date: 2013-02-15

Last Posted Date: 2019-11-04

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 23

Registration Number: NCT01791725

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸
University of California, San Diego, La Jolla, California, United States

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Group 1 ELND005
Drug: Group 2 ELND005

First Posted Date: 2013-01-11

Last Posted Date: 2019-10-21

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 296

Registration Number: NCT01766336

Locations: 🇬🇧
TransitionTIL Investigational Site, Swindon, Wiltshire, United Kingdom

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ELND005
Drug: Placebo

First Posted Date: 2012-11-28

Last Posted Date: 2019-10-21

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 350

Registration Number: NCT01735630

Locations: 🇬🇧
TransitionTIL Investigational Site, Swindon, United Kingdom

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Phase 2

Terminated

Conditions: Bipolar 1 Disorder

Interventions: Drug: ELND005
Drug: Lamotrigine
Drug: Placebo
Drug: Valproic acid

First Posted Date: 2012-08-28

Last Posted Date: 2019-10-21

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 309

Registration Number: NCT01674010

Locations: 🇹🇷
Elan Investigational Site, Istanbul, Turkey

Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Phase 2

Completed

Conditions: Pediatric Growth Hormone Deficiency

Interventions: Drug: MOD-4023
Drug: Somatropin

First Posted Date: 2012-05-07

Last Posted Date: 2020-01-23

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 56

Registration Number: NCT01592500

Locations: 🇸🇰
Children's University Hospital, Kosice, Slovakia
🇬🇷
Children's Hospital "P. A. Kyriakou", Athens, Greece
🇭🇺
Buda Children's Hospital, Budapest, Hungary

and more 1 locations

Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)

Phase 2

Withdrawn

Conditions: Stage 5 Chronic Kidney Disease (CKD)
Secondary Hyperparathyroidism (SHPT)
Hemodialysis (HD)

Interventions: Drug: Lunicalcipol 270
Drug: Lunacalcipol 180

First Posted Date: 2011-10-18

Last Posted Date: 2014-09-22

Lead Sponsor: OPKO Health, Inc.

Registration Number: NCT01453634

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy